A listing of clinical trials currently looking for volunteers to enroll in Melanoma studies. Click on the closest city to find more detailed information on a research study in your area.

http://www.centerwatch.com/clinical-trials/listings/condition/791/melanoma?mp=amf

Really? 

They found that combining statins with drugs that inhibited cyclin-dependent protein kinase enzymes, which regulate and promote the cellular growth of cancer, produced a similar response with both RAS- and BRAF-mutated oncogenes.

http://news.yale.edu/2012/12/13/yale-team-identifies-successful-combination-drug-therapies-melanoma-mutations

(ChemotherapyAdvisor) – Inflammation can trigger reversible losses of antigens from melanoma cell surfaces, cloaking tumors from T-cell detection, report authors of a study published in the journal Nature. The finding might help explain melanoma resistance and relapse after initially-effective immunotherapy, the authors reported.

“Adaptive cell transfer therapies (ACTs) using cytotoxic T-cells that target melanocytic antigens can achieve remissions in patients with metastatic melanomas, but tumors frequently relapse,” wrote Thomas Tüting, MD, Director of the Laboratory for Experimental Dermatology at the Bonn University in Germany. “Our results demonstrate that the phenotypic plasticity of melanoma cells in an inflammatory microenvironment contributes to tumor relapse after initially successful T-cell immunotherapy.” Read More...

Melanoma Research Foundation

Donate Today

Every day the Melanoma Research Foundation works to make the fight against melanoma easier.
Your donation will help us support patients, fund research and advocate for the melanoma community.